JP2001505761A - 組織再生のモジュレーター - Google Patents
組織再生のモジュレーターInfo
- Publication number
- JP2001505761A JP2001505761A JP54298697A JP54298697A JP2001505761A JP 2001505761 A JP2001505761 A JP 2001505761A JP 54298697 A JP54298697 A JP 54298697A JP 54298697 A JP54298697 A JP 54298697A JP 2001505761 A JP2001505761 A JP 2001505761A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- kim
- polypeptide
- protein
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000017423 tissue regeneration Effects 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 156
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 122
- 238000000034 method Methods 0.000 claims abstract description 70
- 235000018102 proteins Nutrition 0.000 claims description 118
- 210000004027 cell Anatomy 0.000 claims description 92
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 59
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 48
- 210000003734 kidney Anatomy 0.000 claims description 47
- 229920001184 polypeptide Polymers 0.000 claims description 44
- 235000001014 amino acid Nutrition 0.000 claims description 43
- 239000013598 vector Substances 0.000 claims description 33
- 150000001413 amino acids Chemical class 0.000 claims description 31
- 210000001519 tissue Anatomy 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 28
- 230000006378 damage Effects 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 108020001507 fusion proteins Proteins 0.000 claims description 22
- 102000037865 fusion proteins Human genes 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 20
- 238000006467 substitution reaction Methods 0.000 claims description 19
- 239000003053 toxin Substances 0.000 claims description 18
- 231100000765 toxin Toxicity 0.000 claims description 18
- 108700012359 toxins Proteins 0.000 claims description 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 230000001086 cytosolic effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 210000002700 urine Anatomy 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 7
- 102000018358 immunoglobulin Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 239000013049 sediment Substances 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 210000005084 renal tissue Anatomy 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 230000004083 survival effect Effects 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 238000003384 imaging method Methods 0.000 claims description 4
- 229940072221 immunoglobulins Drugs 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000008467 tissue growth Effects 0.000 claims description 3
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 230000001172 regenerating effect Effects 0.000 abstract description 7
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 4
- 239000003446 ligand Substances 0.000 description 46
- 239000002299 complementary DNA Substances 0.000 description 42
- 108020004414 DNA Proteins 0.000 description 34
- 241000700159 Rattus Species 0.000 description 24
- 239000000047 product Substances 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 21
- 239000012634 fragment Substances 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 241000701161 unidentified adenovirus Species 0.000 description 13
- 238000001415 gene therapy Methods 0.000 description 12
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000036755 cellular response Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 241000701447 unidentified baculovirus Species 0.000 description 6
- 201000003883 Cystic fibrosis Diseases 0.000 description 5
- 241000700584 Simplexvirus Species 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 241000702421 Dependoparvovirus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000037906 ischaemic injury Diseases 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000002254 renal artery Anatomy 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 230000004989 O-glycosylation Effects 0.000 description 3
- 241000125945 Protoparvovirus Species 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 108010067815 rat Havcr1protein Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 2
- -1 Contains syn Chemical compound 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000010249 in-situ analysis Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000037806 kidney injury Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 210000002796 renal vein Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000004926 tubular epithelial cell Anatomy 0.000 description 2
- 210000005233 tubule cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- PSNCYKUWWBQTLP-UHFFFAOYSA-N (diaminomethylideneamino) cyanate Chemical compound NC(=N)NOC#N PSNCYKUWWBQTLP-UHFFFAOYSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 229940123373 Adenovirus E1A gene Drugs 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102100038591 Endothelial cell-selective adhesion molecule Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101000882622 Homo sapiens Endothelial cell-selective adhesion molecule Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001246312 Otis Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 102000000813 Proto-Oncogene Proteins c-ret Human genes 0.000 description 1
- 108010001648 Proto-Oncogene Proteins c-ret Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940021704 adenovirus vaccine Drugs 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002787 antisense oligonuctleotide Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000002648 nephronophthisis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Electrotherapy Devices (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.腎臓損傷分子(KIM)をコードする精製および単離されたDNAであって、該KI Mは虚血後の哺乳動物腎臓組織において選択的に発現される細胞表面タンパク質 であり、該DNAは、 a)IgGドメイン、ムチンドメイン、膜貫通ドメイン、および細胞質ドメインを 有する307アミノ酸のKIM(KIM-1)ポリペプチド(ここで該IgGドメインは6つの 保存されたシステインを含む)、または b)膜貫通ドメインを有する572アミノ酸のKIMポリペプチド のいずれかをコードする、DNA。 2.クローン3-2(ATCC番号98061)のインサート、クローン1-7(ATCC番号98060 )のインサート、またはクローンH13-10-85のインサートによりコードされるポ リペプチドをコードする、請求項1(a)に記載のDNA。 3.クローン4-7(ATCC番号98062)のインサートによりコードされるポリペプチ ドをコードする、請求項1(b)に記載のDNA。 4.以下から選択されるヌクレオチド配列を有する、請求項1(a)に記載のDNA: a)配列番号1、配列番号2、および配列番号6;または b)配列番号1、配列番号2、および配列番号6のスプライス改変体;または c)配列番号1、配列番号2、および配列番号6の縮重改変体。 5.配列番号1、配列番号2、または配列番号6に相補的な配列を有するDNA。 6.以下から選択されるヌクレオチド配列を有する、請求項1(b)に記載のDNA: a)配列番号4;または b)配列番号4のスプライス改変体;または c)配列番号4の縮重改変体。 7.配列番号4に相補的な配列を有するDNA。 8.IgGドメイン、ムチンドメイン、膜貫通ドメイン、および細胞質ドメインを 有する307アミノ酸のKIM-1ポリペプチドをコードする精製および単離されたDNA であって、該ポリペプチドの配列が、配列番号3および配列番号7から;または 配列番号3および配列番号7と少なくとも40%の相同性を有し、そして配列番号 3および配列番号7のシステイン残基の少なくとも80%を共有するアミノ酸置換 改変体から選択される、DNA。 9.IgGドメイン、ムチンドメイン、膜貫通ドメイン、および細胞質ドメインを 有する307アミノ酸のKIM-1ポリペプチドの可溶性改変体をコードする精製および 単離されたDNAであって、該ポリペプチドの配列が、配列番号3および配列番号 7から;または配列番号3および配列番号7と少なくとも40%の相同性を有し、 そして配列番号3および配列番号7のシステイン残基の少なくとも80%を共有す るアミノ酸置換改変体から選択される、DNA。 10.以下を含む融合タンパク質をコードする精製および単離されたDNA: a)IgGドメイン、ムチンドメイン、膜貫通ドメイン、および細胞質ドメインを 有する307アミノ酸のKIM-1ポリペプチドであって、該ポリペプチドの配列が、配 列番号3および配列番号7から;または配列番号3および配列番号7と少なくと も40%の相同性を有し、そして配列番号3および配列番号7のシステイン残基の 少なくとも80%を共有するアミノ酸置換改変体から選択される、ポリペプチド; および b)免疫グロブリン、毒素、または造影可能化合物。 11.膜貫通ドメインを有する572アミノ酸のKIMポリペプチドをコードする精製 および単離されたDNAであって、該ポリペプチドの配列が、配列番号5から、お よび配列番号5と少なくとも40%の相同性を有し、そして配列番号5のシステイ ン残基の少なくとも80%を共有するアミノ酸置換改変体から選択される、DNA。 12.膜貫通ドメインを有する572アミノ酸のKIMポリペプチドの可溶性改変体を コードする精製および単離されたDNAであって、該ポリペプチドの配列が、配列 番号5から、および配列番号5と少なくとも40%の相同性を有し、そして配列番 号5のシステイン残基の少なくとも80%を共有するアミノ酸置換改変体から選択 される、DNA。 13.以下を含む融合タンパク質をコードする精製および単離されたDNA: a)膜貫通ドメインを有する572アミノ酸のKIMポリペプチドであって、該ポリ ペプチドの配列が、配列番号5から、および配列番号5と少なくとも40%の相同 性を有し、そして配列番号5のシステイン残基の少なくとも80%を共有するアミ ノ酸置換改変体から選択される、ポリペプチド;および b)免疫グロブリン、毒素、または造影可能化合物。 14.その中にインサートとして存在する請求項8、9、10、11、12、ま たは13の核酸を有するベクターであって、該ベクターは必要に応じて該インサ ートに作動可能に連結された発現制御配列を含む、ベクター。 15.請求項14に記載のベクターを含む宿主細胞。 16.ポリペプチド産生方法であって、請求項15に記載の宿主細胞を細胞培養 培地中で培養する工程;および、該宿主細胞内のベクターインサートから発現さ れるKIMポリペプチドを回収する工程、を包含する、方法。 17.精製および単離されたKIMタンパク質であって: a)IgGドメイン、ムチンドメイン、膜貫通ドメイン、および細胞質ドメインを 有する307アミノ酸のKIM-1ポリペプチドであって、該ポリペプチドの配列が、配 列番号3および配列番号7から選択される、ポリペプチド;または b)IgGドメイン、ムチンドメイン、膜貫通ドメイン、および細胞質ドメインを 有する307アミノ酸のKIM-1ポリペプチドであって、該ポリペプチドの配列が、配 列番号3および配列番号7と少なくとも40%の相同性を有し、そして配列番号3 および配列番号7のシステイン残基の少なくとも80%を共有するアミノ酸置換改 変体から選択される、ポリペプチド;または c)膜貫通ドメインを有する572アミノ酸のKIMポリペプチドであって、該ポリ ペプチドの配列が、配列番号5に示される、ポリペプチド;または d)膜貫通ドメインを有する572アミノ酸のKIMポリペプチドであって、該ポリ ペプチドの配列が、配列番号5と少なくとも40%の相同性を有し、そして配列番 号5のシステイン残基の少なくとも80%を共有するアミノ酸置換改変体から選択 される、ポリペプチド、 を含む、タンパク質。 18.請求項17に記載のKIMタンパク質の可溶性改変体。 19.請求項17に記載のKIMタンパク質;および免疫グロブリン、毒素、また は造影可能化合物を含む融合タンパク質。 20.免疫グロブリン、毒素、造影可能化合物、または放射性核種に結合された 、請求項17に記載のKIMタンパク質。 21.請求項17に記載のKIMタンパク質に特異的に結合する抗体。 22.毒素、造影可能化合物、または放射性核種に結合された、請求項21に記 載の抗体。 23.請求項21に記載の抗体を産生するハイブリドーマ。 24.請求項14に記載のベクターの治療における使用。 25.請求項17に記載のKIMタンパク質の治療における使用。 26.請求項18に記載の可溶性改変体KIMタンパク質の治療における使用。 27.請求項19に記載のKIM融合タンパク質の治療における使用。 28.請求項20に記載のKIM結合体の治療における使用。 29.請求項21に記載の抗体の治療における使用。 30.請求項22に記載の抗体結合体の治療における使用。 31.その中に治療有効濃度までの請求項14に記載のベクターが分散された生 理学的に受容可能なキャリアを含む薬学的組成物。 32.その中に治療有効濃度までの請求項17に記載のKIMタンパク質、請求項 18に記載の可溶性改変体KIMタンパク質、請求項19に記載のKIM融合タンパク 質、または請求項20に記載のKIM結合体が分散された生理学的に受容可能なキ ャリアを含む薬学的組成物。 33.その中に治療有効濃度までの請求項21に記載の抗体、または請求項22 に記載の抗体結合体が分散された生理学的に受容可能なキャリアを含む薬学的組 成物。 34.被験体における腎臓損傷の存在またはその消散の過程を評価する方法であ って、腎臓損傷もしくは疾患に罹患している、または腎臓損傷もしくは疾患を発 達する危険にある被験体の尿、血清、または尿沈渣における、請求項8もしくは 11に記載のKIM核酸、または請求項17に記載のKIMポリペプチドの濃度を測定 する工程を包含する、方法。 35.請求項17に記載のKIMポリペプチドを産生する細胞または組織を画像化 する方法であって、該細胞または組織を、造影可能な請求項22に記載のKIM抗 体と接触させる工程を包含する、方法。 36.前記細胞または組織がインビボで被験体中で処理され、そして造影可能な 結合体が被験体に投与される、請求項35に記載の方法。 37.毒素、放射性核種、または造影可能化合物を、請求項17に記載のKIMポ リペプチドを産生する細胞に標的化する方法であって、該細胞を請求項22に記 載のKIM抗体結合体と接触させる工程を包含する、方法。 38.前記細胞がインビボで被験体中で処理されるKIM発現腫瘍細胞であり、そ して前記結合体が該被験体に投与される、請求項37に記載の方法。 39.腎臓疾患に罹患している、または腎臓疾患を発達する危険にある被験体を 処置する方法であって、請求項31,32、または33に記載の薬学的組成物を 該被験体に投与する工程を包含する、方法。 40.被験体における組織成長を促進する方法であって、請求項31,32、ま たは33に記載の薬学的組成物を該被験体に投与する工程を包含する、方法。 41.被験体における損傷された組織の生存を促進する方法であって、請求項3 1,32、または33に記載の薬学的組成物を該被験体に投与する工程を包含す る、方法。 42.前記組織が腎臓組織である、請求項40または41に記載の方法。 43.前記被験体がヒトである、請求項34、36、38、39、40、または 41に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1822896P | 1996-05-24 | 1996-05-24 | |
US60/018,228 | 1996-05-24 | ||
US2344296P | 1996-08-23 | 1996-08-23 | |
US60/023,442 | 1996-08-23 | ||
PCT/US1997/009303 WO1997044460A1 (en) | 1996-05-24 | 1997-05-23 | Modulators of tissue regeneration |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007236021A Division JP4316640B2 (ja) | 1996-05-24 | 2007-09-11 | 組織再生のモジュレーター |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001505761A true JP2001505761A (ja) | 2001-05-08 |
JP4602482B2 JP4602482B2 (ja) | 2010-12-22 |
Family
ID=26690881
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54298697A Expired - Lifetime JP4602482B2 (ja) | 1996-05-24 | 1997-05-23 | 組織再生のモジュレーター |
JP2007236021A Expired - Lifetime JP4316640B2 (ja) | 1996-05-24 | 2007-09-11 | 組織再生のモジュレーター |
JP2008187615A Withdrawn JP2009039111A (ja) | 1996-05-24 | 2008-07-18 | 組織再生のモジュレーター |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007236021A Expired - Lifetime JP4316640B2 (ja) | 1996-05-24 | 2007-09-11 | 組織再生のモジュレーター |
JP2008187615A Withdrawn JP2009039111A (ja) | 1996-05-24 | 2008-07-18 | 組織再生のモジュレーター |
Country Status (27)
Country | Link |
---|---|
US (4) | US6664385B1 (ja) |
EP (2) | EP1655367A1 (ja) |
JP (3) | JP4602482B2 (ja) |
CN (1) | CN1147584C (ja) |
AT (1) | ATE318903T1 (ja) |
AU (1) | AU712289B2 (ja) |
BG (1) | BG64678B1 (ja) |
BR (1) | BR9709115A (ja) |
CA (1) | CA2257851C (ja) |
CZ (1) | CZ295936B6 (ja) |
DE (1) | DE69735364T3 (ja) |
DK (1) | DK0907735T5 (ja) |
EA (1) | EA004402B1 (ja) |
EE (1) | EE04817B1 (ja) |
ES (1) | ES2258793T5 (ja) |
HK (1) | HK1021746A1 (ja) |
HU (1) | HU226205B1 (ja) |
IL (1) | IL127162A (ja) |
IS (1) | IS2636B (ja) |
NO (2) | NO327597B1 (ja) |
NZ (1) | NZ336467A (ja) |
PL (1) | PL188826B1 (ja) |
PT (1) | PT907735E (ja) |
SI (1) | SI0907735T2 (ja) |
SK (1) | SK285461B6 (ja) |
TR (1) | TR199802421T2 (ja) |
WO (1) | WO1997044460A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005500039A (ja) * | 2001-06-29 | 2005-01-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | T細胞調節遺伝子およびその使用方法 |
JP2005505256A (ja) * | 2001-06-01 | 2005-02-24 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Kim−1の分断を阻害するための分子および方法 |
JP2007525434A (ja) * | 2003-03-19 | 2007-09-06 | アブジェニックス インコーポレイテッド | T細胞、免疫グロブリンドメインおよびムチンドメイン1(tim−1)抗原に対する抗体およびその使用。 |
JP2016515514A (ja) * | 2013-03-15 | 2016-05-30 | ライフライン サイエンティフィック インコーポレイテッドLifeline Scientific, Inc. | 臓器または組織の生存性を判定するためのグルコースセンサを備えた搬送装置 |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1147584C (zh) * | 1996-05-24 | 2004-04-28 | 拜奥根有限公司 | 组织再生调节物 |
EP0983357A1 (en) * | 1997-05-23 | 2000-03-08 | Biogen, Inc. | Modulators of tissue regeneration |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
CZ295108B6 (cs) | 1998-03-20 | 2005-05-18 | Benitec Australia Ltd | Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
EP1160321A1 (en) * | 2000-05-31 | 2001-12-05 | Sanofi-Synthelabo | Kidney Injury Novel Gene-1: Isolation and therapeutic applications |
EP1305409B1 (en) | 2000-06-16 | 2009-03-11 | Biogen Idec MA Inc. | Renal regulatory elements and methods of use thereof |
US6812002B2 (en) * | 2000-08-30 | 2004-11-02 | Pfizer Inc. | Osteoactivin protein and nucleic acids encoding the same, compositions and methods of stimulating bone differentiation |
US8709412B2 (en) | 2001-06-29 | 2014-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of TIM receptor activity in combination with cytoreductive therapy |
AU2003228336B2 (en) * | 2002-03-19 | 2009-07-30 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
SI1585546T1 (sl) * | 2002-12-30 | 2008-12-31 | Biogen Idec Inc | KIM-1 antagonisti in uporaba za moduliranje imunskega sistema |
ES2739463T3 (es) * | 2003-03-27 | 2020-01-31 | Childrens Hospital Med Ct | Un método y kit para la detección de la instauración precoz de la lesión de células tubulares renales |
US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
JP2007536260A (ja) | 2004-05-06 | 2007-12-13 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 虚血性および腎毒性障害の軽減および改善用ngal |
RU2283666C9 (ru) * | 2004-05-14 | 2007-03-10 | Бизяев Алексей Вячеславович | Средство для активации восстановления структуры и функции поврежденных тканей и органов |
US20060003345A1 (en) * | 2004-06-30 | 2006-01-05 | Pfizer Inc | RNA bioassay |
ES2818028T3 (es) * | 2004-12-20 | 2021-04-09 | Antibodyshop As | Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales |
CN103751780A (zh) | 2005-03-02 | 2014-04-30 | 比奥根艾迪克Ma公司 | 用于治疗th2介导的疾病的kim-1抗体 |
WO2007059082A1 (en) | 2005-11-10 | 2007-05-24 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
US20080090304A1 (en) * | 2006-10-13 | 2008-04-17 | Barasch Jonathan Matthew | Diagnosis and monitoring of chronic renal disease using ngal |
PL2035835T3 (pl) | 2006-05-30 | 2012-05-31 | Antibodyshop As | Sposoby szybkiej oceny ciężkości urazu |
EP2064553B2 (en) * | 2006-08-07 | 2023-06-07 | Antibodyshop A/S | Diagnostic test to exclude significant renal injury |
WO2008113363A1 (en) * | 2007-03-21 | 2008-09-25 | Bioporto Diagnostics A/S | Diagnostic test for renal injury |
US8846036B2 (en) | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
US20090297479A1 (en) * | 2008-03-28 | 2009-12-03 | Kiyoshi Ariizumi | Dc-hil conjugates for treatment of t-cell disorders |
CN102187220B (zh) * | 2008-08-28 | 2015-08-19 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
JP5947544B2 (ja) * | 2008-08-29 | 2016-07-06 | アスチュート メディカル,インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
NZ619918A (en) * | 2008-10-21 | 2015-04-24 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
CA2740788C (en) * | 2008-10-21 | 2023-03-14 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
AU2009313189B2 (en) | 2008-11-10 | 2014-10-23 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
ES2528799T3 (es) * | 2008-11-22 | 2015-02-12 | Astute Medical, Inc. | Métodos para el pronóstico de insuficiencia renal aguda |
BRPI1007483B1 (pt) * | 2009-01-28 | 2021-11-30 | Bio Preventive Medicine Corporation | Método de diagnóstico de nefropatia in vitro, método in vitro para o monitoramento de progresso de nefropatia, método in vitro para o monitoramento da eficácia de um tratamento de nefropatia, método in vitro de avaliação de toxicidade renal de um agente e kit para diagnóstico de nefropatia |
US9229010B2 (en) | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
EP2462440B1 (en) | 2009-08-07 | 2017-05-17 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US20120264148A1 (en) * | 2009-08-07 | 2012-10-18 | Dashurie Nezieri | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
JP2013510322A (ja) | 2009-11-07 | 2013-03-21 | アスチュート メディカル,インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
CN104698161A (zh) | 2009-12-20 | 2015-06-10 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
CN102791885B (zh) | 2010-02-05 | 2015-09-09 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
US9029093B2 (en) | 2010-02-26 | 2015-05-12 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
JP2013529907A (ja) | 2010-05-24 | 2013-07-25 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | Ngalタンパク質変異体及びその使用 |
AU2011269775B2 (en) | 2010-06-23 | 2015-01-15 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
EP3339859A1 (en) | 2010-06-23 | 2018-06-27 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
DK2672980T3 (en) * | 2011-02-09 | 2018-02-26 | Lavivo Ab | SYNBIOTIC COMPOSITIONS FOR GETTING UP AND RECONSTITUTING GAS MICROFLORA |
WO2013086359A1 (en) | 2011-12-08 | 2013-06-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
EP2925337B1 (en) | 2012-11-21 | 2019-07-03 | The Trustees of Columbia University in the City of New York | Mutant ngal proteins and uses thereof |
EP3361255B1 (en) | 2013-01-17 | 2020-03-11 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
WO2015134671A1 (en) | 2014-03-04 | 2015-09-11 | Targeson, Inc. | Molecular imaging contrast agents and uses thereof |
CA3026502A1 (en) | 2016-06-06 | 2017-12-14 | Astute Medical, Inc. | Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
GB9122820D0 (en) * | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
EP0640094A1 (en) * | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
WO1995021922A2 (en) * | 1994-02-14 | 1995-08-17 | Abbott Laboratories | Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use |
US5622861A (en) * | 1994-08-05 | 1997-04-22 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA encoding hepatitis A virus receptor |
EP0804547A4 (en) * | 1994-08-18 | 1999-11-03 | Univ Columbia | ASSOCIATED SINGLE SEQUENCES OF KAPOSI DISEASE VIRUSES AND USE OF SAID SEQUENCES |
US6069230A (en) * | 1994-11-10 | 2000-05-30 | Promega Corporation | High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications |
US6066322A (en) * | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
CN1147584C (zh) * | 1996-05-24 | 2004-04-28 | 拜奥根有限公司 | 组织再生调节物 |
EP1305409B1 (en) * | 2000-06-16 | 2009-03-11 | Biogen Idec MA Inc. | Renal regulatory elements and methods of use thereof |
JP4527394B2 (ja) * | 2001-06-01 | 2010-08-18 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Kim−1の分断を阻害するための分子および方法 |
US7838220B2 (en) * | 2001-06-29 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes associated with immune disease |
NZ530451A (en) * | 2001-06-29 | 2008-04-30 | Univ Leland Stanford Junior | TIM gene sequences and their use in immunological disorders and cancer |
US7215871B2 (en) * | 2001-07-27 | 2007-05-08 | Thomson Licensing | Changing a playback speed for video presentation recorded in a field structure format |
US7687454B2 (en) * | 2001-12-03 | 2010-03-30 | The University Of British Columbia | Effectors of innate immunity determination |
EP1467759A4 (en) * | 2002-01-30 | 2006-05-31 | Brigham & Womens Hospital | COMPOSITIONS AND METHODS ASSOCIATED WITH TIM-3, TH1-SPECIFIC CELL SURFACE MOLECULE |
AU2003228336B2 (en) * | 2002-03-19 | 2009-07-30 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
SI1585546T1 (sl) * | 2002-12-30 | 2008-12-31 | Biogen Idec Inc | KIM-1 antagonisti in uporaba za moduliranje imunskega sistema |
TW200539890A (en) * | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
AU2005231685A1 (en) * | 2004-03-24 | 2005-10-20 | Telos Pharmaceuticals Llc | Compositions as adjuvants to improve immune responses to vaccines and methods of use |
-
1997
- 1997-05-23 CN CNB971958289A patent/CN1147584C/zh not_active Expired - Lifetime
- 1997-05-23 JP JP54298697A patent/JP4602482B2/ja not_active Expired - Lifetime
- 1997-05-23 EP EP05111979A patent/EP1655367A1/en not_active Withdrawn
- 1997-05-23 AU AU35676/97A patent/AU712289B2/en not_active Expired
- 1997-05-23 PL PL97330313A patent/PL188826B1/pl unknown
- 1997-05-23 DE DE69735364T patent/DE69735364T3/de not_active Expired - Lifetime
- 1997-05-23 AT AT97932145T patent/ATE318903T1/de active
- 1997-05-23 SI SI9730732T patent/SI0907735T2/sl unknown
- 1997-05-23 NZ NZ336467A patent/NZ336467A/xx not_active IP Right Cessation
- 1997-05-23 HU HU9902770A patent/HU226205B1/hu unknown
- 1997-05-23 EA EA199801044A patent/EA004402B1/ru not_active IP Right Cessation
- 1997-05-23 CA CA2257851A patent/CA2257851C/en not_active Expired - Lifetime
- 1997-05-23 PT PT97932145T patent/PT907735E/pt unknown
- 1997-05-23 TR TR1998/02421T patent/TR199802421T2/xx unknown
- 1997-05-23 WO PCT/US1997/009303 patent/WO1997044460A1/en active IP Right Grant
- 1997-05-23 CZ CZ19983813A patent/CZ295936B6/cs not_active IP Right Cessation
- 1997-05-23 DK DK97932145.2T patent/DK0907735T5/da active
- 1997-05-23 EE EE9800409A patent/EE04817B1/xx unknown
- 1997-05-23 IL IL127162A patent/IL127162A/en not_active IP Right Cessation
- 1997-05-23 BR BR9709115A patent/BR9709115A/pt not_active Application Discontinuation
- 1997-05-23 SK SK1609-98A patent/SK285461B6/sk not_active IP Right Cessation
- 1997-05-23 EP EP97932145A patent/EP0907735B9/en not_active Expired - Lifetime
- 1997-05-23 ES ES97932145T patent/ES2258793T5/es not_active Expired - Lifetime
-
1998
- 1998-11-20 IS IS4902A patent/IS2636B/is unknown
- 1998-11-20 NO NO985427A patent/NO327597B1/no not_active IP Right Cessation
- 1998-11-23 US US09/197,970 patent/US6664385B1/en not_active Expired - Lifetime
- 1998-11-30 BG BG102967A patent/BG64678B1/bg unknown
-
2000
- 2000-01-21 HK HK00100386A patent/HK1021746A1/xx not_active IP Right Cessation
-
2003
- 2003-09-04 US US10/655,506 patent/US20050089868A1/en not_active Abandoned
-
2006
- 2006-08-08 US US11/463,227 patent/US20060286031A1/en not_active Abandoned
- 2006-08-08 US US11/463,239 patent/US20070141590A1/en not_active Abandoned
-
2007
- 2007-09-11 JP JP2007236021A patent/JP4316640B2/ja not_active Expired - Lifetime
-
2008
- 2008-07-18 JP JP2008187615A patent/JP2009039111A/ja not_active Withdrawn
-
2009
- 2009-03-03 NO NO20090945A patent/NO20090945L/no not_active Application Discontinuation
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005505256A (ja) * | 2001-06-01 | 2005-02-24 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Kim−1の分断を阻害するための分子および方法 |
JP2005500039A (ja) * | 2001-06-29 | 2005-01-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | T細胞調節遺伝子およびその使用方法 |
JP2007525434A (ja) * | 2003-03-19 | 2007-09-06 | アブジェニックス インコーポレイテッド | T細胞、免疫グロブリンドメインおよびムチンドメイン1(tim−1)抗原に対する抗体およびその使用。 |
JP2012001561A (ja) * | 2003-03-19 | 2012-01-05 | Abgenix Inc | T細胞、免疫グロブリンドメインおよびムチンドメイン1(tim−1)抗原に対する抗体およびその使用。 |
JP2014144971A (ja) * | 2003-03-19 | 2014-08-14 | Abgenix Inc | T細胞、免疫グロブリンドメインおよびムチンドメイン1(tim−1)抗原に対する抗体およびその使用。 |
JP2017048240A (ja) * | 2003-03-19 | 2017-03-09 | アムジェン・フレモント・インコーポレイテッドAmgen Fremont, Inc. | T細胞、免疫グロブリンドメインおよびムチンドメイン1(tim−1)抗原に対する抗体およびその使用。 |
JP2018150305A (ja) * | 2003-03-19 | 2018-09-27 | アムジェン・フレモント・インコーポレイテッドAmgen Fremont, Inc. | T細胞、免疫グロブリンドメインおよびムチンドメイン1(tim−1)抗原に対する抗体およびその使用。 |
JP2016515514A (ja) * | 2013-03-15 | 2016-05-30 | ライフライン サイエンティフィック インコーポレイテッドLifeline Scientific, Inc. | 臓器または組織の生存性を判定するためのグルコースセンサを備えた搬送装置 |
US10420337B2 (en) | 2013-03-15 | 2019-09-24 | Lifeline Scientific, Inc. | Transporter with a glucose sensor for determining viability of an organ or tissue |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001505761A (ja) | 組織再生のモジュレーター | |
KR100587556B1 (ko) | 신경 및 신장 증식을 자극하기 위한 RET리간드(RetL) | |
KR100499600B1 (ko) | 신생 세포 성장을 억제하기 위한 방법 및 조성물 | |
US6861509B1 (en) | Antibodies to Ret and RetL3 | |
JP2002516572A (ja) | 組織の再生の調節 | |
WO2001016169A2 (en) | RET LIGAND 5 (Retl5) FROM HUMAN AND MOUSE | |
KR100498530B1 (ko) | 조직재생조절물질 | |
KR100554901B1 (ko) | 신경및신장증식을자극하기위한RET리간드(RetL) | |
MXPA98009812A (en) | Modulators of the regeneration of the tej |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040402 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060718 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061017 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070522 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070911 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20070817 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20071004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080304 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080307 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080404 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080409 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080501 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080605 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20081113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100818 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100930 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131008 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |